BioLineRx Highlights GLIX1’s 68–85% Brain Exposure and PARP Synergy at ASCO
Two GLIX1 abstracts (e14072, e13129) will appear at ASCO 2026, covering glioblastoma CNS tumors and metastatic breast cancer PARP inhibitor synergies. Preclinical data show 68–85% brain exposure in mice and potent antitumor effects in glioblastoma xenografts, while a first-in-human Phase 1/2a trial enrolled up to 30 GBM patients in March.
1. ASCO Abstracts Spotlight
BioLineRx and Hemispherian AS will present two GLIX1 abstracts at the ASCO 2026 Annual Meeting (May 29–June 2). Abstract e14072 focuses on central nervous system tumors, while e13129 examines GLIX1 combined with PARP inhibitors in metastatic breast cancer.
2. Preclinical Efficacy Data
GLIX1 restores TET2 activity to induce DNA strand breaks. In mice, brain exposure reached 68–85% of plasma levels, and glioblastoma xenograft models (U87-MG, SNB-19) showed strong antitumor responses at oral dosing.
3. Synergy with PARP Inhibitors
In vitro studies across diverse cancer cell lines demonstrated that GLIX1 plus multiple PARP inhibitors produced consistent cytotoxic synergy, providing a mechanistic rationale for combined therapy in cancers with intact homologous recombination repair.
4. Phase 1/2a Trial Status and Outlook
The open-label Phase 1/2a trial, launched in March, is conducting dose escalation in up to 30 recurrent and progressive GBM patients to determine the maximum tolerated dose and preliminary efficacy, with dose-escalation results expected in 2027 and updates slated for H2 2026.